Biophan bei 0,50 Euro und dann das !


Seite 2 von 3
Neuester Beitrag: 19.10.05 19:31
Eröffnet am:11.08.04 16:33von: leobmwAnzahl Beiträge:69
Neuester Beitrag:19.10.05 19:31von: NolteLeser gesamt:15.525
Forum:Börse Leser heute:14
Bewertet mit:


 
Seite: < 1 |
| 3 >  

1539 Postings, 8049 Tage aida73ist nicht jeder nur ein Mitläufer

 
  
    #26
22.12.04 00:28
jeder sollte doch selbst entscheiden, was er mit seinem Geld macht.Wenn es dann schiefgeht,sollte aber auch kein anderer die Schuld bekommen.Man muss die Börse und gerade die Foren,als Aktionär,so gut kennen,dass man die Pusher und Basher genau herausfiltern kann.
Mitläufer hört sich so nach Pusher an und einige springen mit auf,so dass man sie abzocken kann.Ist es wirklich so?Ich denke so sollte ein solides Börsengeschäft nicht laufen.auf Pushs reinfllen,geht meist immer die Hose und sollte nie Gegenstnd eines Investment sein.
Ach,und Leute,diskutiert bitte ruhig und gelassen und startet hier keine Anmache!  

573 Postings, 7334 Tage PossibilityPusher und Basher genau herausfiltern ?

 
  
    #27
22.12.04 00:52
so ein Blödsinn !!!"!!!

hier gibt es nur 3 Typen :

-   Leute die was riskieren

-   Leute die eine Aktie beobachten um dann was zu riskieren ( auch mit eigenem Thread)

-   Leute die ihren Senf überall dazugeben, von Prognosen partizipieren und den größten Hals haben wenn eine Aktie nicht läuft !

Absurd ist es nur das genau diese Leute meinen sie wären die größten !!!!

So ein Schwachsinn


  kostenlose gif sammlung gifs bilder Männer  

10092 Postings, 7552 Tage NoRiskNoFunKkkaaaaaauuuuffffeeeeennnn ;-)

 
  
    #28
22.12.04 00:54
Shorts auf Kaffee...Servus leo  

573 Postings, 7334 Tage Possibilityist es denn die possibility ?

 
  
    #29
22.12.04 01:02
grüß dich norisk !!

naaaaaaaaa schauen wir mal !

einen speziellen den ich dann madig machen kann ?

  kostenlose gif sammlung gifs bilder Männer  

10092 Postings, 7552 Tage NoRiskNoFunHaste grad was auf der watch otc? o. T.

 
  
    #30
22.12.04 01:03

573 Postings, 7334 Tage PossibilityBICO - immer für ein paar Prozente gut

 
  
    #31
22.12.04 01:15
wird bei mir schon langsam zum "long"  was langweilig !

kaum Risiko nur Gewinne - immer das gleiche !

wenn du jetzt bei 0,048 kaufst - kannst du noch dieses Jahr mit fetten Gewinn wieder raus !



  kostenlose gif sammlung gifs bilder Männer  

573 Postings, 7334 Tage Possibilitywas sagen diese "Longs" immer

 
  
    #32
22.12.04 01:42
der Trend ist dein Freund ?????



Chart

Splits:none
Last Trade:0.048Trade Time:3:53PM ETChange:Up 0.001 (2.13%)Prev Close:0.047Open:0.048Bid:0.046 x 5000Ask:0.048 x 50001y Target Est:N/ADay's Range:0.046 - 0.0552wk Range:0.029 - 0.585Volume:1,927,850Avg Vol (3m):3,722,396Market Cap:N/AP/E (ttm):N/AEPS (ttm):N/ADiv & Yield:N/A (N/A)
More on BICO.OB...

Bad credit home equity rates -Up to 4 offers in 60 seconds.

Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a FriendGet Basic Chart(s) for Another Symbol:  Symbol LookupHistorical PricesMarket Overview

  kostenlose gif sammlung gifs bilder Männer  

305 Postings, 8178 Tage optimanBiophan: Ausgehende Luft?

 
  
    #33
22.12.04 10:52

306 Postings, 7605 Tage manager01Moin Alfred! o. T.

 
  
    #34
22.12.04 22:32

573 Postings, 7334 Tage Possibilityna ihr Börsenkumpel - hahahhaaaaaa !

 
  
    #35
23.12.04 16:59

14 Postings, 7274 Tage Rutenstarjep o. T.

 
  
    #36
23.12.04 17:28

14 Postings, 7274 Tage Rutenstarjep.. o. T.

 
  
    #37
23.12.04 17:28

306 Postings, 7605 Tage manager01was macht Alfred eigentlich heute??? o. T.

 
  
    #38
24.12.04 13:33

199 Postings, 7293 Tage Janasdejaja - so ist das !

 
  
    #39
07.01.05 13:02

Biophan Executes Letter of Intent to Acquire German-Based Advanced MRI Technology Company

ROCHESTER, N.Y.
Biophan Technologies, Inc.Carolyn Hotchkiss, 585-214-2407 ORPress Interviews:Jennifer Gould, 212-843-8037

Deal to Bring Biophan Next-Generation Medical Devices, Patents, and Increased European Market Presence

Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, has entered into a letter of intent to acquire a leading German-based developer of MRI-safe and image-compatible technology solutions and biomedical devices. Under the arrangement, Biophan will also acquire the exclusive license to fifteen issued and pending patents covering imaging of devices such as stents and other vascular implants, significantly expanding the Company's intellectual property portfolio. The parties are expected to execute the definitive agreement and complete due diligence on or before January 31, 2005.

When completed, the acquisition of AMRIS GmbH, of Castrop-Rauxel, Germany, will provide Biophan with innovative products, technologies, and scientific expertise that extend Biophan's intellectual property portfolio of medical solutions in the fast-growing marketplace of products and procedures that are compatible with Magnetic Resonance Imaging (MRI).

"The AMRIS technology complements Biophan's very effectively and expands our scientific capabilities significantly," said Biophan's CEO, Michael Weiner. "Equally important, the acquisition will provide an important boost to our marketing capabilities, particularly in Europe, where major manufacturers of MRI machines and biomedical devices are based and where much of the leading research in MRI-guided interventional medicine is currently being conducted."

Following the acquisition, AMRIS will be renamed Biophan Europe, and Michael Friebe, Ph.D., will continue as president. Dr. Friebe will join the Biophan board of directors. AMRIS' Scientific director and Chief Technology Officer, Andreas Melzer, M.D., will join the Biophan Scientific Advisory Board and lead many of Biophan's device developments.

"Even more important to us than the very valuable patents that we are licensing exclusively under this agreement are the extraordinary people in AMRIS who are joining the Biophan team," said Mr. Weiner.

Dr. Friebe is a scientist and entrepreneur trained in MRI related physics at the University of California at San Francisco, one of the world's leading biomedical research centers, and at the University of Witten in Germany. He later started and then sold NEUROMED AG, later renamed UMS NEUROMED after being acquired by United Medical Systems (UMS), a publicly-traded German company. Dr. Friebe is a well-regarded radiology/cardiology oriented entrepreneur with an extensive business and customer network.

Dr. Melzer is a professor of applied biomedical engineering, Director and Chairman of the Board at the Institute for Medical Technologies and Management in Medicine INSITE med. at the University of Applied Sciences in Gelsenkirchen, Germany. He also holds a clinical position as part-time staff radiologist at the Department of Diagnostic and Interventional Radiology at St. Mary's Hospital Buer in Gelsenkirchen, Germany. Dr. Melzer has over 15 years of experience in the development of medical technology for laparo-endoscopic surgery, interventional radiology, Interventional and Intraoperative MRI and MR compatible Robotics, surgical instrumentation, and Nitinol devices. He has co-invented and patented some of the most exciting and important innovations in imaging of medical devices under MRI and he continues to develop and invent. As a practicing physician in radiology, Dr. Melzer has a unique understanding of the needs of patients, the medical device community, the physicians conducting procedures under MRI, and the scientific solutions that are possible. He has co-invented more than 30 patents and has authored over 150 publications. Additionally, Dr. Melzer is engaged as co-organizer, chairman, and invited speaker of various medical conferences and is a board member of several medical societies, as well as professional committees.

"We are extremely excited that we have found a partner who is equally committed to the MRI technology and who provides complementary technologies, products, and markets," commented Dr. Friebe. "Professor Melzer's innovative product ideas and market foresight together with the Biophan resources will be an ideal combination."

In addition, as part of the transaction, Biophan will acquire the worldwide exclusive rights to a significant patent portfolio totaling fifteen issued and pending patents covering critical capabilities needed by the medical industry as the use of MRI interventional medicine and MRI diagnostics for examination of stents and other implants becomes standard medical procedure. This acquisition and related licensing deal will bring the Biophan patent portfolio to 107 U.S. patents, licenses, or applications, in addition to 12 pending European patents.

Among the AMRIS technology assets are an MRI-visible catheter marker, an MRI-visible stent, and a series of MRI-visible medical devices in development. The Company's management and research staff provide world-class intellectual expertise in the field of MRI compatibility, and have been awarded several million dollars in upcoming grants from government agencies to develop its next-generation biomedical technology for MRI.

AMRIS and its principals have contractual and consulting agreements with many of the world's leading biomedical device and MRI machine manufacturers.

MRI, one of medicine's most important imaging technologies, uses magnetic fields to create pictures of the interior of the human body. The powerful magnetic and electromagnetic fields, however, can trigger dangerous or sometimes fatal interactions with many implanted medical devices, such as cardiac pacemakers. As a result, MRI is contraindicated for a large patient population, restricting important treatment options for those patients and their physicians. Certain implantable devices, such as stents, cannot be viewed for restenosis reoccurrence under MRI, due to signal interference caused by the stent, which sets up a Faraday Cage effect. As a result, patients with these devices have to undergo invasive procedures with administration of nephrotoxic allergenic contrast agents under radiation-emitting x-ray devices. With the Biophan/AMRIS technology, restenosis reoccurrence can be safely viewed under MRI.

About AMRIS GmbH

AMRIS is a developer of active MRI systems for enhanced visualization and therapy in the MRI environment. Among the company technologies are advanced MRI-compatible and active endovascular stents, filters, valves, occluders, and catheters. AMRIS is also the holder of two issued U.S. patents and multiple pending U.S. and European patents. The company is based in Castrop-Rauxel and Gelsenkirchen, Germany. More information can be found at www.amris.de.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 104 U.S. patents, licenses or applications. This total includes 25 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 70 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


Copyright © 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
News Copyright © 2004 Interest!ALERT All rights reserved.

 

38 Postings, 7576 Tage BrabusEs gibt News und der Kurs explodiert

 
  
    #40
07.01.05 13:56
Biophan Executes Letter of Intent to Acquire German-Based

Advanced MRI Technology Company



Deal To Bring Biophan Next-Generation Medical Devices, Patents,

and Increased European Market Presence



ROCHESTER, N.Y.--January 7, 2005--Biophan Technologies, Inc (OTCBB: BIPH), a developer of next-generation biomedical technology, has entered into a letter of intent to acquire a leading German-based developer of MRI-safe and image-compatible technology solutions and biomedical devices.  Under the arrangement, Biophan will also acquire the exclusive license to fifteen issued and pending patents covering imaging of devices such as stents and other vascular implants, significantly expanding the Company’s intellectual property portfolio.  The parties are expected to execute the definitive agreement and complete due diligence on or before January 31, 2005.



When completed, the acquisition of AMRIS GmbH, of Castrop-Rauxel, Germany, will provide Biophan with innovative products, technologies, and scientific expertise that extend Biophan’s intellectual property portfolio of medical solutions in the fast-growing marketplace of products and procedures that are compatible with Magnetic Resonance Imaging (MRI).  



“The AMRIS technology complements Biophan’s very effectively and expands our scientific capabilities significantly,” said Biophan’s CEO, Michael Weiner.  “Equally important, the acquisition will provide an important boost to our marketing capabilities, particularly in Europe, where major manufacturers of MRI machines and biomedical devices are based and where much of the leading research in MRI-guided interventional medicine is currently being conducted.”



Following the acquisition, AMRIS will be renamed Biophan Europe, and Michael Friebe, Ph.D., will continue as president.  Dr. Friebe will join the Biophan board of directors.  AMRIS’ Scientific director and Chief Technology Officer, Andreas Melzer, M.D., will join the Biophan Scientific Advisory Board and lead many of Biophan’s device developments.



“Even more important to us than the very valuable patents that we are licensing exclusively under this agreement are the extraordinary people in AMRIS who are joining the Biophan team,” said Mr. Weiner.  



Dr. Friebe is a scientist and entrepreneur trained in MRI related physics at the University of California at San Francisco, one of the world’s leading biomedical research centers, and at the University of Witten in Germany.  He later started and then sold NEUROMED AG, later renamed UMS NEUROMED after being acquired by United Medical Systems (UMS), a publicly-traded German company.  Dr. Friebe is a well-regarded radiology/cardiology oriented entrepreneur with an extensive business and customer network.



Dr. Melzer is a professor of applied biomedical engineering, Director and Chairman of the Board at the Institute for Medical Technologies and Management in Medicine INSITE med. at the University of Applied Sciences in Gelsenkirchen, Germany.  He also holds a clinical position as part-time staff radiologist at the Department of Diagnostic and Interventional Radiology at St. Mary’s Hospital Buer in Gelsenkirchen, Germany.  Dr. Melzer has over 15 years of experience in the development of medical technology for laparo-endoscopic surgery, interventional radiology, Interventional and Intraoperative MRI and MR compatible Robotics, surgical instrumentation, and Nitinol devices.  He has co-invented and patented some of the most exciting and important innovations in imaging of medical devices under MRI and he continues to develop and invent.  As a practicing physician in radiology, Dr. Melzer has a unique understanding of the needs of patients, the medical device community, the physicians conducting procedures under MRI, and the scientific solutions that are possible.  He has co-invented more than 30 patents and has authored over 150 publications.  Additionally, Dr. Melzer is engaged as co-organizer, chairman, and invited speaker of various medical conferences and is a board member of several medical societies, as well as professional committees.  



“We are extremely excited that we have found a partner who is equally committed to the MRI technology and who provides complementary technologies, products, and markets,” commented Dr. Friebe.  “Professor Melzer’s innovative product ideas and market foresight together with the Biophan resources will be an ideal combination.”



In addition, as part of the transaction, Biophan will acquire the worldwide exclusive rights to a significant patent portfolio totaling fifteen issued and pending patents covering critical capabilities needed by the medical industry as the use of MRI interventional medicine and MRI diagnostics for examination of stents and other implants becomes standard medical procedure.  This acquisition and related licensing deal will bring the Biophan patent portfolio to 107 U.S. patents, licenses, or applications, in addition to 12 pending European patents.



Among the AMRIS technology assets are an MRI-visible catheter marker, an MRI-visible stent, and a series of MRI-visible medical devices in development.  The Company’s management and research staff provide world-class intellectual expertise in the field of MRI compatibility, and have been awarded several million dollars in upcoming grants from government agencies to develop its next-generation biomedical technology for MRI.  



AMRIS and its principals have contractual and consulting agreements with many of the world’s leading biomedical device and MRI machine manufacturers.



MRI, one of medicine’s most important imaging technologies, uses magnetic fields to create pictures of the interior of the human body.  The powerful magnetic and electromagnetic fields, however, can trigger dangerous or sometimes fatal interactions with many implanted medical devices, such as cardiac pacemakers. As a result, MRI is contraindicated for a large patient population, restricting important treatment options for those patients and their physicians.  Certain implantable devices, such as stents, cannot be viewed for restenosis reoccurrence under MRI, due to signal interference caused by the stent, which sets up a Faraday Cage effect.  As a result, patients with these devices have to undergo invasive procedures with administration of nephrotoxic allergenic contrast agents under radiation-emitting x-ray devices.  With the Biophan/AMRIS technology, restenosis reoccurrence can be safely viewed under MRI.
 

199 Postings, 7293 Tage Janasdena geht doch seit 11.08 nur gut !

 
  
    #41
20.01.05 20:38

       
       

549 Postings, 8026 Tage Taodonmoin aida

 
  
    #42
24.01.05 17:15
Ich bin Raus letze Woche schon ... die Seitwärtsbewegung gefällt mir nicht konnte aber noch zu 1,04 raus und da ich bei 64 eingestiegen bin war das schon okay .... bin jetzt zu 48Cent bei Newmarket Technologie rein ... Spitzenkurs heute 56Cent ... war also gut. Prima Start für dieses Jahr nur Chinadot.com muss ich noch halten bis sie wieder bei 4 Euro sind ....also so bis Dezember diesen Jahres *grummel* !! So mein Alter her hat mir 2000 zum Spielen gegeben .... werd mir jetzt mal was nicht allzu spekulatives suchen .. Chirio  

549 Postings, 8026 Tage Taodonoh hups

 
  
    #43
24.01.05 17:17
das sollte a bischel kleiner !;)))))  

549 Postings, 8026 Tage TaodonLuft ist raus

 
  
    #44
26.01.05 13:29
Ihr solltet die gewinne erstmal mitnehmen  

306 Postings, 7605 Tage manager01herrrrrlich!

 
  
    #45
26.01.05 14:52
Endlich fällt der kurs wieder, ich genieße das bild!  

221 Postings, 7543 Tage Aktionär240Warum eigentlich?

 
  
    #46
26.01.05 17:26
Warum doch gute news........  

221 Postings, 7543 Tage Aktionär240.

 
  
    #47
26.01.05 17:29
waren doch gute news wollte ich meinen  

549 Postings, 8026 Tage Taodonweil

 
  
    #48
26.01.05 17:32
das n Zockerwert ist ... okay mal ein solider aber solange die nicht durch die 1,10 gehen läuft da nichts und da das erst passiert wenn aus den 1001 Guten nachricht mal nen bischel Cash geworden ist ... meientwegen bei den halb oder quartalszahlen(ir wollen ja hoffen das da wiedererwarten schnell was kommt.) hat wie man sieht so manch einer mit ein paar mehr Stücken im Depot sich dieser endledigt um den verbleibenden gewinn zu sichern oder schlimmeres zu vermeiden ... wie auch immer ich kaufe mir wieder ein paar ins Depot wenn die die Tage wider schnuckelig unter 80 sind ... so ist der Markt Leute passiert nichts wird mit ner anderen Aktie gespielt.... Chirio ...(wär kommt gleich mit Fussi spielen ...hmmm???  

549 Postings, 8026 Tage Taodonguck

 
  
    #49
26.01.05 17:46
dir mal Bid- und ask an das geht heut noch weiterrunter ... 83 cent ist glaubich realistisch  

4568 Postings, 7233 Tage bradettiKursmanipulation

 
  
    #50
27.01.05 13:51

sag ich da nur. Damit gewisse Leute nochmal billig abfassen können.
Gestern hätte man nochmal nachkaufen sollen und nicht in Panik verfallen.

Biophan ist nun mal volatil. Da sollte man sich nicht immer gleich nervös machen lassen.

An den Aussichten hat sich doch nichts geändert!!! Naja, mein Mitleid all denen, die gestern ausgestoppt wurden - das ist natürlich blöd, aber die, die gestern zittrig verkauft haben - mein Respekt, genau falsch gesetzt

Ich glaube an Biophan und grüße alle Gleichgesinnten

 

Seite: < 1 |
| 3 >  
   Antwort einfügen - nach oben